Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $9.00 target price on shares of Trevena in a research report on Tuesday, April 2nd.

Trevena Stock Up 5.2 %

TRVN stock opened at $0.37 on Monday. Trevena has a twelve month low of $0.30 and a twelve month high of $3.28. The company has a market cap of $6.78 million, a PE ratio of -0.12 and a beta of 1.10. The business’s 50-day simple moving average is $0.50 and its 200 day simple moving average is $0.58. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 8.35.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena at the end of the most recent quarter. 13.56% of the stock is owned by hedge funds and other institutional investors.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.